We consider denosumab (XGEVA®) a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting.
We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG.
Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.
We cannot recommend reimbursement of Ipilimumab at the submitted price.
Reimbursement not Recommended
Following review, we recommend reimbursement of vernakalant in the hospital setting.
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland
Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.